Skip to main content
Man Who Predicted March 2020 Crash Says 2021 Is The Time
If you've got money invested in the stock market, but are confused as to what to do next...This is the can't-miss interview of 2021...
Learn more here!

SPRB Insider Trading (Spruce Biosciences)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $6,750,000.00
Insider Selling (Last 12 Months): $226,686.30

Spruce Biosciences Insider Trading History Chart

Spruce Biosciences Share Price & Price History

$15.41
▼ -0.17 (-1.09%)
As of 05/7/2021 01:00 AM ET
Days: 30 | 90 | 365
Man Who Predicted March 2020 Crash Says 2021 Is The Time
If you've got money invested in the stock market, but are confused as to what to do next...This is the can't-miss interview of 2021...
Learn more here!

Spruce Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2021Camilla V SimpsonDirectorSell14,045$16.14$226,686.3014,045View SEC Filing Icon  
10/14/2020Bali MuralidharDirectorBuy200,000$15.00$3,000,000.00View SEC Filing Icon  
10/14/2020Venture Fund Iii L RivervestMajor ShareholderBuy250,000$15.00$3,750,000.004,739,336View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Spruce Biosciences (NASDAQ:SPRB)

Institutional Buying and Selling by Quarter

Spruce Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/7/2021BlackRock Inc.345,306$5.73M0.0%+4.0%1.482%Search for SEC Filing on Google Icon
4/23/2021Strs Ohio2,400$39K0.0%+41.2%0.010%Search for SEC Filing on Google Icon
2/19/2021PFM Health Sciences LP529,311$12.87M0.5%N/A2.280%Search for SEC Filing on Google Icon
2/19/2021JPMorgan Chase & Co.188,827$4.59M0.0%N/A0.813%Search for SEC Filing on Google Icon
2/17/2021Sands Capital Management LLC787,007$19.13M0.0%N/A3.390%Search for SEC Filing on Google Icon
2/16/2021Nuveen Asset Management LLC22,666$0.55M0.0%N/A0.098%Search for SEC Filing on Google Icon
2/16/2021Charles Schwab Investment Management Inc.40,352$0.98M0.0%N/A0.174%Search for SEC Filing on Google Icon
2/13/2021American International Group Inc.4,050$98K0.0%N/A0.017%Search for SEC Filing on Google Icon
2/12/2021Caas Capital Management LP10,000$0.24M0.0%N/A0.043%Search for SEC Filing on Google Icon
2/12/2021Laurion Capital Management LP20,000$0.49M0.0%N/A0.086%Search for SEC Filing on Google Icon
2/12/2021AWM Investment Company Inc.40,000$0.97M0.1%N/A0.172%Search for SEC Filing on Google Icon
2/12/2021Credit Suisse AG25,713$0.63M0.0%N/A0.111%Search for SEC Filing on Google Icon
2/11/2021Northern Trust Corp79,204$1.93M0.0%N/A0.341%Search for SEC Filing on Google Icon
2/11/2021Citigroup Inc.1,282$31K0.0%N/A0.006%Search for SEC Filing on Google Icon
2/9/2021Wells Fargo & Company MN3,724$90K0.0%N/A0.016%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp13,492$0.33M0.0%N/A0.058%Search for SEC Filing on Google Icon
2/8/2021New York State Common Retirement Fund3,200$78K0.0%N/A0.014%Search for SEC Filing on Google Icon
2/6/2021Granite Point Capital Management L.P.100,000$2.43M0.1%N/A0.431%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.332,032$8.07M0.0%N/A1.430%Search for SEC Filing on Google Icon
2/4/2021Aisling Capital Management LP1,205,511$29.31M5.0%N/A5.193%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Spruce Biosciences logo
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Read More on Spruce Biosciences

Today's Range

Now: $15.41
$15.28
$15.70

50 Day Range

MA: $16.27
$14.80
$17.97

52 Week Range

Now: $15.41
$14.18
$35.60

Volume

91,450 shs

Average Volume

53,188 shs

Market Capitalization

$359.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Spruce Biosciences?

Spruce Biosciences' top insider investors include:
  1. Venture Fund Iii L Rivervest (Major Shareholder)
  2. Camilla V Simpson (Director)
  3. Bali Muralidhar (Director)

Who are the major institutional investors of Spruce Biosciences?

Spruce Biosciences' top institutional shareholders include:
  1. BlackRock Inc. — 1.48%
  2. Strs Ohio — 0.01%

Which institutional investors are buying Spruce Biosciences stock?

During the previous quarter, SPRB stock was bought by institutional investors including:
  1. BlackRock Inc.
  2. Strs Ohio
Within the previous year, these company insiders have bought Spruce Biosciences stock:
  1. Venture Fund Iii L Rivervest (Major Shareholder)
  2. Camilla V Simpson (Director)
Your 15 Minute Workday… (Make Extra Cash from Home)
Some people binge watch Netflix… Hulu…or HBO shows. And some people turn their downtime into cash. James made $2,275 in just 19 minutes…all thanks to something called The 15 Minute Workday. The average trade makes 12% in just 5 days (factoring winners and losers) which is out of this world.
Click here to start
pixel